The latest developments in Ewing’s sarcoma tend to show that Insulin-like Growth Factor 1 Receptor (IGF1R) targeting agents are promising [36, 37], but none was efficient enough to lead to a phase III trial. This evidence concerns the gene IGF1R and Ewing sarcoma.